Quisovalimab

奎索利单抗

Report date: 2025/07/04 16:55:36

Base Information

Drug NameQuisovalimab
Drug Alias NameCERC-002AEVI-002MDGN-002SAR-252067AVTX-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor superfamily member 14 inhibitors
TargetsTumor necrosis factor superfamily member 14
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, AdultAcute Lung Injury +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLa Jolla Pharmaceutical CompanyKyowa Hakko Kirin Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAevi Genomic MedicineAvalo Therapeutics Inc
Inactive CompaniesAevi Genomic Medicine Llc
Active IndicationsAsthma
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, AdultAcute Lung Injury +[5] 

Other Information

ATC CodeN/A
Related LinksN/A